Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.
J Med Chem
; 50(10): 2297-300, 2007 May 17.
Article
in En
| MEDLINE
| ID: mdl-17441705
ABSTRACT
Alogliptin is a potent, selective inhibitor of the serine protease dipeptidyl peptidase IV (DPP-4). Herein, we describe the structure-based design and optimization of alogliptin and related quinazolinone-based DPP-4 inhibitors. Following an oral dose, these noncovalent inhibitors provide sustained reduction of plasma DPP-4 activity and a lowering of blood glucose in animal models of diabetes. Alogliptin is currently undergoing phase III trials in patients with type 2 diabetes.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Piperidines
/
Pyrimidinones
/
Uracil
/
Dipeptidyl Peptidase 4
/
Quinazolinones
/
Dipeptidyl-Peptidase IV Inhibitors
/
Hypoglycemic Agents
Language:
En
Journal:
J Med Chem
Journal subject:
QUIMICA
Year:
2007
Document type:
Article